Board Changes

FOR IMMEDIATE RELEASE 16 August 2018

Cello Health plc

("Cello", the "Company", or the "Group")

Board Changes

Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, is pleased to announce the appointment, with immediate effect, of two independent non-executive directors to the Company's board of directors (the "Board"). The new Board members, Clifford Tompsett and Jo LeCouilliard, both have extensive experience in the pharmaceutical industry.

Clifford Tompsett was until recently a senior partner at PriceWaterhouseCoopers LLP ("PwC"), with responsibility for the firm's global cross border IPO practice. For a number of years Clifford led the firm's UK and European activities in the pharmaceutical sector, advising on many of the large deals in the industry. He was at PwC for 38 years, and is a qualified chartered accountant. Clifford will head the Board's Audit Committee and he will also be the Company's Senior Independent Director.

Jo LeCouilliard was until recently at GlaxoSmithKline plc where she held senior executive positions globally with roles in regions including the United States and Asia. Jo has also held senior hospital management positions at BMI Healthcare, and is currently a non-executive director of Circassia Pharmaceuticals plc. 

In line with the plans announced at the Annual General Meeting on 10 May 2018, Paul Hamilton and Will David have both stood down as non-executive directors with immediate effect, each having served as members of the Board for more than a decade.

Mark Scott, CEO of Cello, said:

"Both Paul Hamilton and Will David have been non-executive directors of the Company since its formation. Throughout that time, they have helped the Board shape the Group into a leading international business serving predominantly health orientated clients. We are profoundly grateful for their efforts, and wish them both the best for the future.

"I am delighted that the Group has secured the services of two, highly experienced and capable new non-executive directors with deep experience across the pharmaceutical industry. The Board very much looks forward to working with Clifford and Jo as we shape the future growth path for the Group."

Regulatory information

Mr. Tompsett and Ms. LeCouilliard do not have any interests in the ordinary shares of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies in respect of the appointments of Mr. Tompsett and Ms. LeCouilliard.

Enquiries:

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com